Evidence map›Paper›PMID 31678970›Full record

ArticleJournal of investigative medicine : the official publication of the American Federation for Clinical Research2020

MiR-3150b-3p inhibits the progression of colorectal cancer cells via targeting GOLPH3.

Weiqing Zhang, Xiaoyan Chen, Junzhi Jia

Abstract read
In one paragraph

Article in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Clinicopathological implications of miR-3127 in melanoma.Journal of pathology and translational medicine · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer.International journal of molecular sciences · 2020
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weiqing Zhang *Department of General Surgery, Wuwei People's Hospital, Wuwei, Gansu, China.
Xiaoyan Chen *Day Care Ward, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Junzhi JiaDay Care Ward, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China junzhijia_12@126.com.ORCID 0000-0002-3720-3405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the function of miR-3150b-3p in malignant behaviors of colorectal cancer (CRC). The tumor-inhibitive effect of miR-3150b-3p was determined by cell viability, invasion, and migration assays. The influence of miR-3150b-3p on the expression of Golgi phosphoprotein 3 (GOLPH3) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway was evaluated by luciferase reporter, qRT-PCR and western blot analysis. MiR-3150b-3p was markedly decreased in CRC cell lines compared with colonic mucosal epithelial cell line (FHC). Furthermore, miR-3150b-3p inhibited malignant biological behaviors by targeting GOLPH3, an oncogene in CRC. Additionally, we suggested that miR-3150b-3p ameliorated CRC tumorigenesis in vitro through GOLPH3-mediated JAK2/STAT3 pathway. MiR-3150b-3p might function as a promising tumor suppressor in CRC.

Indexed as

Cell MovementColorectal NeoplasmsDisease ProgressionHCT116 CellsHT29 CellsHumansMembrane ProteinsMicroRNAsGOLPH3 protein, humanMembrane ProteinsMicroRNAsMIRN3150a microRNA, humancolorectal cancerGOLPH3JAK2/STAT3miR-3150b-3ptumor suppressor

Identifiers

PMID31678970
PMCPMC7063393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.